Last update 21 Dec 2024

Filanesib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Filanesib (USAN/INN), Filanesib-hydrochloride, ARRY-520
Target
Mechanism
KIF11 inhibitors(Kinesin-like protein 1 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

Structure

Molecular FormulaC20H22F2N4O2S
InChIKeyLLXISKGBWFTGEI-FQEVSTJZSA-N
CAS Registry885060-09-3

External Link

KEGGWikiATCDrug Bank
D11754Filanesib-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 3
AT
-
Multiple MyelomaPhase 3
BE
-
Multiple MyelomaPhase 3
CZ
-
Multiple MyelomaPhase 3
DE
-
Multiple MyelomaPhase 3
GR
-
Multiple MyelomaPhase 3
HU
-
Multiple MyelomaPhase 3
ES
-
Multiple MyelomaPhase 3
SE
-
Multiple MyelomaPhase 3
GB
-
Refractory Multiple MyelomaPhase 2
US
01 May 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
Multiple Myeloma
alpha 1-acid glycoprotein (AAG)
-
ngftdaikeh(whciicfteh) = xprirohevu bywharfokc (qjiyqawhke )
Positive
01 Feb 2021
Phase 1
63
Dexamethasone+filanesib+carfilzomib
(Part A)
urpjddeono(rlytytgtqr) = Among 30 patients treated at the MTD for the Part A dose-expansion cohorts with filanesib 1.5 mg/m2, carfilzomib 20/27 mg/m2, and dexamethasone 4 mg,A total of 14 patients were treated at the MTD for the Part B dose-expansion cohort with filanesib 1.5 mg/m2, carfilzomib 20/56 mg/m2, and dexamethasone (4 mg prior to each carfilzomib dose in 10 patients and 40 mg on days 1, 8, and 15 in 4 patients due to protocol amendment) ulroemnsmm (ndltpyroqm )
Positive
01 Oct 2019
Dexamethasone+filanesib+carfilzomib
(Part B)
Phase 1/2
-
Dexamethasone+Empegfilgrastim+Filanesib
zulroejzsg(wmmbeistqq) = sgremoejld vgwuudsydx (vybtcopwqx )
Positive
01 Dec 2017
-
Phase 2
247
(Patients with low AAG)
xfllbulsgm(llbeszuthd) = qrmhkivydl uaalfscetb (hbeynfzkof )
-
21 May 2015
(Patients with high AAG)
xfllbulsgm(llbeszuthd) = lfgkwwjimf uaalfscetb (hbeynfzkof )
Phase 1
41
(Initial Schedules)
nzoykvrptu(ccjvsyohem) = tcdyaiftxu dmnzzmxgrz (cgdgsypveb )
Positive
01 Apr 2015
(Alternate Schedules)
nzoykvrptu(ccjvsyohem) = gkoqjxtzoa dmnzzmxgrz (cgdgsypveb )
Phase 1
Refractory Leukemia
KSP inhibition
36
prtjtiqcbt(udgtkaywpb) = yjgncrzjzj nsavcuyfxz (rgiitsyzcn )
Negative
15 Jul 2012
Phase 1
34
dqftnpekqf(jxocewnota) = vlsatijnow ggrhcxjnjj (rahaakhlde )
-
20 May 2010
Phase 1
15
vorfrpwfay(qphndziiko) = xsdbsmxmxs gtkekhbest (pmbusqngwy )
-
20 May 2009
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free